Skip to content
DataLookout
Menu

NCT07196501

A Study to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 8 words
    • Interventions modified
    • Study sites: 60 to 61
    • Study title revised
  2. Minor Trial sites expanded: 45 → 60 locationsv4
  3. Minor Study sites: 31 to 45v3
  4. Minor Study sites: 4 to 31v2
  5. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Time from Randomization to Relapse
Timeframe: From randomization to the earliest of relapse or end-of study (up to approximately 32 months)

Arms and interventions

Open-label Treatment Period: OsavampatorExperimental

Participants will be treated with osavampator during the open-label treatment period.

Randomized Double-blind Maintenance Period: OsavampatorExperimental

Participants will be randomized to receive osavampator during the randomized double-blind maintenance period.

Randomized Double-blind Maintenance Period: PlaceboExperimental

Participants will be randomized to receive matching placebo during the randomized double-blind maintenance period.

Drugs: Osavampator, Placebo

Sites

61 sites in 11 countries

United States 24, Canada 5, Bulgaria 4, Italy 4, South Korea 4, Spain 4, Taiwan 4, Australia 3, Estonia 3, Poland 3, Serbia 3